Friday, March 24, 2023 | Back issues
Courthouse News Service Courthouse News Service


MANHATTAN — Days after reaching a $495 million settlement with the United States about its Medicaid classification of EpiPens, Mylan faces a federal class action alleging securities fraud. The drugmaker has been hounded of late by consumers and Congress over EpiPen price-gouging.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.